



**340B  
2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



## **340B Coalition Summer Conference 2022**

August 1-3, 2022 – National Harbor, MD

Jointly provided by Partners for Advancing Clinical Education (PACE) and 340B Health

### **Educational Objectives**

Upon completion of this activity, participants should be able to:

- See individual session descriptions and learning objectives

### **Joint Accreditation Statement**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and 340B Health. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Pharmacy Continuing Education**

PACE designates this continuing education activity for 15.75 contact hour(s) (1.575 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Numbers – see listing below)

Type of Activity: Knowledge

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

### **Instructions for Credit**

In order to obtain your CE credit, please follow the steps below at the conclusion of the activity:

1. Visit <https://www.paceducation.com/340BSC22>
2. Select a session in which you would like to claim credit.
3. Enter your profile information.
4. Complete the session evaluation.
5. Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.



**340B  
2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Partners for Advancing Clinical Education

**Monday, August 1, 2022**

Time	Session Title	UAN	Contact Hours
8:15am – 9:30am	340B Essentials Part 1: What is 340B and How Does it Work?	JA4008073-9999-22-011-L04-P; JA4008073-9999-22-011-L04-T	1.25
	Specialty Pharmacy Part 1: Specialty Drugs and the Intersection with 340B	JA4008073-9999-22-012-L04-P; JA4008073-9999-22-012-L04-T	1.25
10:30am – 11:45am	340B Essentials Part 2: An Introduction to Program Compliance	JA4008073-9999-22-013-L04-P; JA4008073-9999-22-013-L04-T	1.25
	Specialty Pharmacy Part 2: Leveraging Specialty Pharmacy	JA4008073-9999-22-014-L04-P; JA4008073-9999-22-014-L04-T	1.25
1:00pm – 3:00pm	Welcome and Opening Remarks, The State of 340B, and Updates From HRSA	JA4008073-9999-22-015-L04-P; JA4008073-9999-22-015-L04-T	2.0
4:00pm – 5:15pm	Community Health Centers	JA4008073-9999-22-016-L04-P; JA4008073-9999-22-016-L04-T	1.25
	Family Planning, STD Clinics, and Other Non-Hospital Providers	JA4008073-9999-22-017-L04-P; JA4008073-9999-22-017-L04-T	1.25
	HIV/AIDS Clinics, ADAPs, and HIV Service Providers	JA4008073-9999-22-018-L04-P; JA4008073-9999-22-018-L04-T	1.25
	Hemophilia Treatment Centers	JA4008073-9999-22-019-L04-P; JA4008073-9999-22-019-L04-T	1.25
	Hospitals	JA4008073-9999-22-020-L04-P; JA4008073-9999-22-020-L04-T	1.25
	340B Service Providers	JA4008073-9999-22-021-L04-P; JA4008073-9999-22-021-L04-T	1.25
<b>Maximum Credits available on Monday, August 1, 2022</b>			<b>5.75</b>

**Tuesday, August 2, 2022**

Time	Session Title	UAN	Contact Hours
7:30am – 8:45am	Advancing the Role of Pharmacy Technicians in 340B	JA4008073-9999-22-022-L04-P; JA4008073-9999-22-022-L04-T	1.25
	340B Lessons from the Field, Part 1	JA4008073-9999-22-023-L04-P; JA4008073-9999-22-023-L04-T	1.25
9:00am – 10:00am	Washington Update: 340B Implications of the Midterm Elections for this Congress and Beyond	JA4008073-9999-22-024-L04-P; JA4008073-9999-22-024-L04-T	1.0
11:00am – 12:15am	Track 1: 340B Operations & Compliance - Managing 340B Drug Shortages	JA4008073-9999-22-025-L04-P; JA4008073-9999-22-025-L04-T	1.25



**340B  
2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



	Track 1: 340B Operations & Compliance - 340B Lessons from the Field, Part 2	JA4008073-9999-22-026-L04-P; JA4008073-9999-22-026-L04-T	1.25
	Track 2: Hot Topics - Navigating Manufacturer Contract Pharmacy Restrictions and Exceptions	JA4008073-9999-22-027-L04-P; JA4008073-9999-22-027-L04-T	1.25
	Track 2: Hot Topics - Current State of Prescription Drug Pricing Reform in the Senate	JA4008073-9999-22-028-L04-P; JA4008073-9999-22-028-L04-T	1.25
	Track 3: 340B Patient Impact - Clinical Pharmacy Services Supported by 340B	JA4008073-9999-22-029-L04-P; JA4008073-9999-22-029-L04-T	1.25
	Track 4: Special Interests - Marketing for Success in the Age of Pharmacy Technicians	JA4008073-9999-22-030-L04-P; JA4008073-9999-22-030-L04-T	1.25
	Track 4: Special Interests - Grantee Compliance Roundtable	JA4008073-9999-22-031-L04-P; JA4008073-9999-22-031-L04-T	1.25
	Track 4: Special Interests - Ryan White Clinics: Latest Trends and Topics	JA4008073-9999-22-032-L04-P; JA4008073-9999-22-032-L04-T	1.25
1:45pm – 3:00pm	Track 1: 340B Operations & Compliance - Contract Pharmacy Operations: Set Up and Run	JA4008073-9999-22-033-L04-P; JA4008073-9999-22-033-L04-T	1.25
	Track 1: 340B Operations & Compliance - HRSA 340B Program Integrity for Covered Entities	JA4008073-9999-22-034-L04-P; JA4008073-9999-22-034-L04-T	1.25
	Track 2: Hot Topics - Hospital Roundtable: Sharing Experiences with Contract Pharmacy Restrictions #1	JA4008073-9999-22-035-L04-P; JA4008073-9999-22-035-L04-T	1.25
	Track 2: Hot Topics - Federal and State Payer Developments and Trends	JA4008073-9999-22-036-L04-P; JA4008073-9999-22-036-L04-T	1.25
	Track 3: 340B Patient Impact - The Role of 340B in HIV Prevention	JA4008073-9999-22-037-L04-P; JA4008073-9999-22-037-L04-T	1.25
	Track 3: 340B Patient Impact - Demonstrating 340B Value: Research and Case Studies	JA4008073-9999-22-038-L04-P; JA4008073-9999-22-038-L04-T	1.25
	Track 4: Special Interests - CHC Expert Session 1: Specialty Pharmacy: Challenges and Opportunities for Health Centers	JA4008073-9999-22-039-L04-P; JA4008073-9999-22-039-L04-T	1.25

	Track 4: Special Interests - Rural Conversations, Part 1: Optimizing 340B for Small Rural Hospitals	JA4008073-9999-22-040-L04-P; JA4008073-9999-22-040-L04-T	1.25
4:00pm – 5:15pm	Track 1: 340B Operations & Compliance - At the Crossroads of 340B and Related Compliance Issues	JA4008073-9999-22-041-L04-P; JA4008073-9999-22-041-L04-T	1.25
	Track 1: 340B Operations & Compliance - Contract Pharmacy Compliance: Oversight by the Entity	JA4008073-9999-22-042-L04-P; JA4008073-9999-22-042-L04-T	1.25
	Track 2: Hot Topics - 340B Audit Policy Update: Enforcement of Patient Definition	JA4008073-9999-22-043-L04-P; JA4008073-9999-22-043-L04-T	1.25
	Track 2: Hot Topics - Ryan White Clinics Roundtable: Sharing Experiences with Contract Pharmacy Restrictions	JA4008073-9999-22-044-L04-P; JA4008073-9999-22-044-L04-T	1.25
	Track 3: 340B Patient Impact - The Pharmacist's Role in Promoting Health Equity	JA4008073-9999-22-045-L04-P; JA4008073-9999-22-045-L04-T	1.25
	Track 4: Special Interests - CHC Expert Session 2: Quantifying the 340B Contribution to the Health Care Delivery System	JA4008073-9999-22-046-L04-P; JA4008073-9999-22-046-L04-T	1.25
	Track 4: Special Interests - 340B Challenges with Information Technology: Potential Solutions	JA4008073-9999-22-047-L04-P; JA4008073-9999-22-047-L04-T	1.25
	Track 4: Special Interests - Rural Conversations, Part 2: 340B in Rural Communities	JA4008073-9999-22-048-L04-P; JA4008073-9999-22-048-L04-T	1.25
<b>Maximum Credits available on Tuesday, August 2, 2022</b>			<b>6</b>

### Wednesday, August 3, 2022

Time	Session Title	UAN	Contact Hours
6:45am – 8:00am	Breakfast: 340B Lessons from the Field, Part 3	JA4008073-9999-22-049-L04-P; JA4008073-9999-22-049-L04-T	1.25
8:00am – 8:30am	HRSA 340B Prime Vendor Program (PVP) Update	JA4008073-9999-22-050-L04-P; JA4008073-9999-22-050-L04-T	.5
8:30am – 9:30am	Keynote Remarks by Jerome Adams, 20th Surgeon General of the United States	JA4008073-9999-22-051-L04-P; JA4008073-9999-22-051-L04-T	1.0



10:30am – 11:45am	Track 1: 340B Operations & Compliance - 340B Analysts: Data & Dashboards	JA4008073-9999-22-052-L04-P; JA4008073-9999-22-052-L04-T	1.25
	Track 1: 340B Operations & Compliance - 340B Audit Policy Update: Enforcement of Duplicate Discount Prohibition	JA4008073-9999-22-053-L04-P; JA4008073-9999-22-053-L04-T	1.25
	Track 1: 340B Operations & Compliance - 340B Lessons from the Field, Part 4	JA4008073-9999-22-054-L04-P; JA4008073-9999-22-054-L04-T	1.25
	Track 2: Hot Topics - Optimizing 340B Across the Entity	JA4008073-9999-22-055-L04-P; JA4008073-9999-22-055-L04-T	1.25
	Track 2: Hot Topics - Hospital Roundtable: Sharing Experiences with Contract Pharmacy Restrictions #2	JA4008073-9999-22-056-L04-P; JA4008073-9999-22-056-L04-T	1.25
	Track 2: Hot Topics - CHC Roundtable: Sharing Experiences with Contract Pharmacy Restrictions	JA4008073-9999-22-057-L04-P; JA4008073-9999-22-057-L04-T	1.25
	Track 3: 340B Patient Impact - 340B: Meeting Patients Where They Are	JA4008073-9999-22-058-L04-P; JA4008073-9999-22-058-L04-T	1.25
	Track 3: 340B Patient Impact - COVID Therapies and 340B	JA4008073-9999-22-059-L01-P; JA4008073-9999-22-059-L01-T	1.25
	Track 4: Special Interests - CHC Expert Session 3: Health Center Owned Pharmacy: Lessons Learned Along the Way	JA4008073-9999-22-060-L04-P; JA4008073-9999-22-060-L04-T	1.25
	Track 4: Special Interests - Communicating the 340B Success Story	JA4008073-9999-22-061-L04-P; JA4008073-9999-22-061-L04-T	1.25
<b>Maximum Credits available on Wednesday, August 3, 2022</b>			<b>4</b>

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### **Faculty and Disclosure of Conflicts of Interest**

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The **faculty** reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

<b>Faculty</b>	<b>Conflicts of Interest</b>
Jerome Adams	Consultant/Advisor/Speaker: Avita Specialty Pharmacy, Atea Pharmaceuticals, Total Diversity CRO
Ronah Alexander	Has no relevant financial relationship(s) with ineligible companies to disclose
Mathew Allsbrook	Consultant/Advisor/Speaker: Biogen, Coherus, Pfizer
Jeffrey Akers	Has no relevant financial relationship(s) with ineligible companies to disclose
Matthew Atkins	Has no relevant financial relationship(s) with ineligible companies to disclose
Anthony Armstrong	Has no relevant financial relationship(s) with ineligible companies to disclose
Alan Arville	Has no relevant financial relationship(s) with ineligible companies to disclose
Jennifer Austin	Has no relevant financial relationship(s) with ineligible companies to disclose
Sue Barnhart	Has no relevant financial relationship(s) with ineligible companies to disclose
Jody Becker	Has no relevant financial relationship(s) with ineligible companies to disclose
Matthew Bertsch	Has no relevant financial relationship(s) with ineligible companies to disclose
Jeff Blake	Has no relevant financial relationship(s) with ineligible companies to disclose
Karen Bowe	Has no relevant financial relationship(s) with ineligible companies to disclose





**340B**  
**2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Jesse Breidenbach	Has no relevant financial relationship(s) with ineligible companies to disclose
Jacqueline Brown	Has no relevant financial relationship(s) with ineligible companies to disclose
Christy Bryant	Employee: Macro Helix, a subsidiary of McKesson
Samantha Burch	Has no relevant financial relationship(s) with ineligible companies to disclose
Racheal Butler	Has no relevant financial relationship(s) with ineligible companies to disclose
Jason Campbell	Has no relevant financial relationship(s) with ineligible companies to disclose
David Christian	Has no relevant financial relationship(s) with ineligible companies to disclose
Emily Cook	Has no relevant financial relationship(s) with ineligible companies to disclose
Nicole Crase	Has no relevant financial relationship(s) with ineligible companies to disclose
Chris Crosswhite	Has no relevant financial relationship(s) with ineligible companies to disclose
Christina Carrizales Cortez	Has no relevant financial relationship(s) with ineligible companies to disclose
Sumona DasGupta	Has no relevant financial relationship(s) with ineligible companies to disclose
Jeff Davis	Has no relevant financial relationship(s) with ineligible companies to disclose
Meetal Desai	Has no relevant financial relationship(s) with ineligible companies to disclose
Kathryn DiBitetto	Has no relevant financial relationship(s) with ineligible companies to disclose
Sean Dickson	Has no relevant financial relationship(s) with ineligible companies to disclose
ThanhSon Doan	Has no relevant financial relationship(s) with ineligible companies to disclose
Greg Doggett	Has no relevant financial relationship(s) with ineligible companies to disclose
Brittany Edwards	Has no relevant financial relationship(s) with ineligible companies to disclose
Emeka Egwim	Has no relevant financial relationship(s) with ineligible companies to disclose
Anthony Esgro	Has no relevant financial relationship(s) with ineligible companies to disclose
Ricardo Fernandez	Has no relevant financial relationship(s) with ineligible companies to disclose
Kristin Fox-Smith	Has no relevant financial relationship(s) with ineligible companies to disclose



**340B**  
**2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Partners for Advancing Clinical Education

Michael French	Has no relevant financial relationship(s) with ineligible companies to disclose
Devki Gajera	Has no relevant financial relationship(s) with ineligible companies to disclose
Alan Glazar	Has no relevant financial relationship(s) with ineligible companies to disclose
Michael Glomb	Has no relevant financial relationship(s) with ineligible companies to disclose
Myles Goldman	Has no relevant financial relationship(s) with ineligible companies to disclose
Tristan Greer	Has no relevant financial relationship(s) with ineligible companies to disclose
Jay Gupta	Has no relevant financial relationship(s) with ineligible companies to disclose
Jesse Hall	Has no relevant financial relationship(s) with ineligible companies to disclose
Jennifer Hagen	Has no relevant financial relationship(s) with ineligible companies to disclose
Victoria Hanson	Has no relevant financial relationship(s) with ineligible companies to disclose
Chris Hatwig	Has no relevant financial relationship(s) with ineligible companies to disclose
Tim Horn	Has no relevant financial relationship(s) with ineligible companies to disclose
ShaiAnn Howard	Employee: AllianceRx Walgreen Pharmacy
Jason Jenders	Consultant/Advisor/Speaker: Gilead Sciences, Louvir
Chad Johnson	Has no relevant financial relationship(s) with ineligible companies to disclose
Kamile Johnson	Consultant/Advisor/Speaker: Janssen (HIV)
Robert Johnson	Has no relevant financial relationship(s) with ineligible companies to disclose
Vivian Johnson	Has no relevant financial relationship(s) with ineligible companies to disclose
Brett Jordan	Has no relevant financial relationship(s) with ineligible companies to disclose
Seema Kakar	Has no relevant financial relationship(s) with ineligible companies to disclose
Elizabeth Karan	Has no relevant financial relationship(s) with ineligible companies to disclose
Rusol Karralli	Has no relevant financial relationship(s) with ineligible companies to disclose
Daniel Katavic	Has no relevant financial relationship(s) with ineligible companies to disclose
Shane Kelley	Has no relevant financial relationship(s) with ineligible companies to disclose
Ben Kelly	Employee: Maxor National Pharmacy Services





**340B**  
**2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Katelyn Keys	Has no relevant financial relationship(s) with ineligible companies to disclose
Vacheria Keys	Has no relevant financial relationship(s) with ineligible companies to disclose
Dennis Killian	Consultant/Advisor/Speaker: Xellia, Pai Pharmaceuticals, Omnicell, Baxter
Mathew Krah	Has no relevant financial relationship(s) with ineligible companies to disclose
Megan Lengerman	Has no relevant financial relationship(s) with ineligible companies to disclose
Olivia Little	Has no relevant financial relationship(s) with ineligible companies to disclose
Andrew Lowe	Has no relevant financial relationship(s) with ineligible companies to disclose
Mark Malahosky	Has no relevant financial relationship(s) with ineligible companies to disclose
Tim Mallett	Employee: Nuvem Health
Alex Mansour	Has no relevant financial relationship(s) with ineligible companies to disclose
Mary Elizabeth Marr	Has no relevant financial relationship(s) with ineligible companies to disclose
Michael McCaughan	Has no relevant financial relationship(s) with ineligible companies to disclose
Jane McLaughlin	Has no relevant financial relationship(s) with ineligible companies to disclose
Emily McCloskey Schreiber	Has no relevant financial relationship(s) with ineligible companies to disclose
Karen McCombs	Has no relevant financial relationship(s) with ineligible companies to disclose
Mindy McGrath	Has no relevant financial relationship(s) with ineligible companies to disclose
Colleen Meiman	Has no relevant financial relationship(s) with ineligible companies to disclose
Steven Miller	Previously owned individual publicly traded stocks in Walmart
Amanda Nagrotsky	Has no relevant financial relationship(s) with ineligible companies to disclose
Lisa Nelson	Has no relevant financial relationship(s) with ineligible companies to disclose
Kirstia Neuendorf	Has no relevant financial relationship(s) with ineligible companies to disclose
Harry Norsworthy	Has no relevant financial relationship(s) with ineligible companies to disclose
Mark Ogunsusi	Has no relevant financial relationship(s) with ineligible companies to disclose
Adetoro Oriairo	Has no relevant financial relationship(s) with ineligible companies to disclose

Robert Owens	Has no relevant financial relationship(s) with ineligible companies to disclose
Stephanie Arnold Pang	Has no relevant financial relationship(s) with ineligible companies to disclose
Cristie Pellegrini	Has no relevant financial relationship(s) with ineligible companies to disclose
Kriss Petrovskis	Has no relevant financial relationship(s) with ineligible companies to disclose
Donna Petty	Has no relevant financial relationship(s) with ineligible companies to disclose
Derek Pihl	Has no relevant financial relationship(s) with ineligible companies to disclose
Vinny Polito	Has no relevant financial relationship(s) with ineligible companies to disclose
Josheph Pugliese	Has no relevant financial relationship(s) with ineligible companies to disclose
Nicolas Rebmann	Has no relevant financial relationship(s) with ineligible companies to disclose
Jason Reddish	Has no relevant financial relationship(s) with ineligible companies to disclose
Tayiana Reed	Has no relevant financial relationship(s) with ineligible companies to disclose
Hannah Rowell	Has no relevant financial relationship(s) with ineligible companies to disclose
Lisa Scholz	Has no relevant financial relationship(s) with ineligible companies to disclose
Emily Schreiber	Has no relevant financial relationship(s) with ineligible companies to disclose
Dominic Seraphin	Has no relevant financial relationship(s) with ineligible companies to disclose
Arsalan Shah	Has no relevant financial relationship(s) with ineligible companies to disclose
Jinga Shah	Has no relevant financial relationship(s) with ineligible companies to disclose
Mayank Shah	Has no relevant financial relationship(s) with ineligible companies to disclose
Nirav Shah	Employee: AmerisourceBergen
Sima Shah	Has no relevant financial relationship(s) with ineligible companies to disclose
Sean Singh	Has no relevant financial relationship(s) with ineligible companies to disclose
Amanda Smith	Has no relevant financial relationship(s) with ineligible companies to disclose
Rhodie Smith	Has no relevant financial relationship(s) with ineligible companies to disclose



**340B**  
**2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Zak Smith	Has no relevant financial relationship(s) with ineligible companies to disclose
Cescilly Smith-Jenkins	Has no relevant financial relationship(s) with ineligible companies to disclose
Richard Sorian	Has no relevant financial relationship(s) with ineligible companies to disclose
Rich Sprung	Has no relevant financial relationship(s) with ineligible companies to disclose
Caroline Steinberg	Has no relevant financial relationship(s) with ineligible companies to disclose
Shannon Stephenson	Has no relevant financial relationship(s) with ineligible companies to disclose
Barbara Straub Williams	Has no relevant financial relationship(s) with ineligible companies to disclose
Charles Stubbs	Has no relevant financial relationship(s) with ineligible companies to disclose
Rebecca Swartz	Has no relevant financial relationship(s) with ineligible companies to disclose
Maureen Testoni	Has no relevant financial relationship(s) with ineligible companies to disclose
Kelle Tillman	Has no relevant financial relationship(s) with ineligible companies to disclose
Roya Tran	Has no relevant financial relationship(s) with ineligible companies to disclose
Sue Veer	Has no relevant financial relationship(s) with ineligible companies to disclose
Anthony Velasquez	Has no relevant financial relationship(s) with ineligible companies to disclose
Andrea Weddle	Consultant: Merck
Matt Webber	Has no relevant financial relationship(s) with ineligible companies to disclose
James Welborn	Has no relevant financial relationship(s) with ineligible companies to disclose
Leah West	Has no relevant financial relationship(s) with ineligible companies to disclose
Jangus Whitner	Individual publicly traded stocks/stock options: Moderna, Pfizer
Michelle Wiest	Has no relevant financial relationship(s) with ineligible companies to disclose
Alexandra Williams	Has no relevant financial relationship(s) with ineligible companies to disclose
Cynthia Williams	Has no relevant financial relationship(s) with ineligible companies to disclose
Bibi Wishart	Has no relevant financial relationship(s) with ineligible companies to disclose
Robin Hayes Wishom	Has no relevant financial relationship(s) with ineligible companies to disclose



**340B**  
**2022**

340B Coalition  
Summer Conference  
AUGUST 1-3, 2022



Gilda Yeboah	Has no relevant financial relationship(s) with ineligible companies to disclose
R. Logan Yoho	Has no relevant financial relationship(s) with ineligible companies to disclose

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The 340B Health planner, Steven Miller, BSPHarm, previously owned individual publicly traded stocks in Walmart.

**Questions?**

For Partners for Advancing Clinical Education (PACE) website and assessments or questions about credits, please email [contactus@partnersed.com](mailto:contactus@partnersed.com).

For questions about the 340B Coalition agenda topics or content, please email [education@340bhealth.org](mailto:education@340bhealth.org).